Kenya Kobayashi

Dr. Kenya Kobayashi


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in Auris Nasus Larynx
Verified
Journal Article
Closed access
KKKenya Kobayashi
Kenya Kobayashi
KNKazunari Nakao
Kazunari Nakao
SKSadahiro Kishishita
Sadahiro Kishishita
NTNoriko Tamaruya
Noriko Tamaruya
HMHiroko Monobe
Hiroko Monobe
AKAtsushi Kihara
Atsushi Kihara

2 July 2014 in ORL
Verified
Journal Article
Closed access
PDF file
KKKenya Kobayashi
Kenya Kobayashi
YSYuki Saito
Yuki Saito
GOGo Omura
Go Omura
MAMizuo Ando
Mizuo Ando
TSTakashi Sakamoto
Takashi Sakamoto
TATakahiro Asakage
Takahiro Asakage
Purpose: Head and neck squamous cell carcinoma of an unknown primary site (HNSCCUP) is a heterogeneous group of tumors that includes the human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. To investigate the relationship between HNSCCUP and HPV, we reviewed p16 overexpression and HPV DNA in lymph node metastases and examined their correlation with the primary site and clinical features. Materials and Methods: Thirty-three patients with HNSCCUP were retrospectively studied. Dissected neck metastases were analyzed for p16 overexpression by immunohistochemistry, and the presence of HPV DNA was investigated by in situ hybridization. Results: Of the 33 patients, 8 (24%) exhibited p16 overexpression. p16-positive lymph node metastases contained significantly more HPV DNA and were most frequently associated with occult primary lesions in the oropharynx and a favorable prognosis. Patients with a lower alcohol consumption, only level II/III metastasis, and cystic lymph node metastasis tended to have p16 overexpression. Conclusions: This is the first report on the relationship of HNSCCUP with p16 and HPV DNA status in Asian patients. In total, 24% of the HNSCCUP patients were p16 positive. p16 overexpression in neck metastasis was predictive of both an occult primary lesion in the oropharynx and an association with HPV infection. Alcohol consumption, location, and features of neck metastasis were correlated with p16 expression.

12 May 2015 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
KKKenya Kobayashi
Kenya Kobayashi
MAMizuo Ando
Mizuo Ando
YSYuki Saito
Yuki Saito
KKKenji Kondo
Kenji Kondo
GOGo Omura
Go Omura
TYTatsuya Yamasoba
Tatsuya Yamasoba

28 December 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
GOGo Omura
Go Omura
MAMizuo Ando
Mizuo Ando
YEYasuhiro Ebihara
Yasuhiro Ebihara
YSYuki Saito
Yuki Saito
KKKenya Kobayashi
Kenya Kobayashi
Tatsuya YamasobaTatsuya Yamasoba
Tatsuya Yamasoba
TP53 is the most frequently mutated gene in human cancers. Previous studies reported that TP53 mutations correlated with poor prognoses in patients with head and neck squamous cell carcinoma (HNSCC). However, the relationship between TP53 mutations and hypopharyngeal squamous cell carcinoma (HPSCC) is not known. The current study aimed to evaluate TP53 mutation status as a predictive biomarker in patients with HPSCC. We retrospectively reviewed the clinical charts of 57 HPSCC patients treated with initial surgery between 2008 and 2014. TP53 mutation status was determined by Sanger sequencing, and patients were classified into wild-type, missense mutation, and truncating mutation groups. Additionally, p53 expression was determined using immunohistochemistry in surgical specimens. TP53 mutations were identified in 39 (68%) patients. The 3-year disease-specific survival (DSS) rate of wild-type, missense mutation, and truncating mutation group were 94%, 61%, and 43%, respectively. The TP53 mutation group displayed significantly worse DSS and overall survival rates than the wild-type group (P = 0.01 and P = 0.007, respectively). Multivariate analyses revealed that the presence of TP53 mutations and ≥4 metastatic lymph nodes were independent adverse prognostic factors for HPSCC. p53 immunopositivity was detected in 22 patients, including 5 (28%) and 17 (71%) patients in the wild-type and missense mutation groups, whereas none of the patients with truncating mutation exhibited p53 immunopositivity (P = 0.0001). The TP53 mutation status correlated with poor prognosis in surgically treated HPSCC patients. Specifically, truncating mutations which were not detected by p53 immunohistochemistry were predictive of worst survival.

26 August 2016 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
KKKenya Kobayashi
Kenya Kobayashi
FMFumihiko Matsumoto
Fumihiko Matsumoto
MKMakoto Kodaira
Makoto Kodaira
TMTaisuke Mori
Taisuke Mori
NMNaoya Murakami
Naoya Murakami
SYSeiichi Yoshimoto
Seiichi Yoshimoto
Adult rhabdomyosarcoma (RMS) is a highly aggressive tumor. Multidisciplinary treatment is important. However, the role of surgery is controversial. The purpose of this study was to reveal the role of a delayed primary excision (DPE) after induction chemotherapy (IC) in localized nonmetastatic adult head and neck RMS. We retrospectively reviewed 24 adult head and neck RMS. Treatment was classified into the following two groups: the DPE group, who received IC followed by surgery, postoperative radiotherapy, and adjuvant chemotherapy (17 patients); the chemoradiotherapy (CRT) group, who received IC followed by chemoradiotherapy (seven patients). We analyzed the efficacy of IC, local control rate (LCR), and overall survival (OS). In the DPE group, 10 patients (59%) underwent complete surgical resection. In the evaluation of the surgical specimens, 14 patients (82%) had residual viable tumors after IC. The response to IC was significantly associated with the 3-year LCR (CR/PR vs. SD/PD: 100% vs. 33%, P = 0.0014). In patients with good response to chemotherapy, the DPE group had a significantly better 3-year LCR compared with that of the CRT group (DPE group vs. CRT group, 100% vs. 44%, P = 0.018). However, the treatment modalities were not associated with OS (DPE group vs. CRT group, 65% vs. 57%: P = 0.98). The recurrence patterns differed according to treatments, and distant metastases were more frequent in the DPE group. DPE may impact local control of localized nonmetastatic adult head and neck RMS. Poor response to IC is a risk factor for local recurrence.

10 June 2023 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
KKKenya Kobayashi
Kenya Kobayashi
NHNobuhiro Hanai
Nobuhiro Hanai
SYSeiichi Yoshimoto
Seiichi Yoshimoto
YSYuki Saito
Yuki Saito
AHAkihiro Homma
Akihiro Homma
Given the low incidence, variety of histological types, and heterogeneous biological features of head and neck sarcomas, there is limited high-quality evidence available to head and neck oncologists. For resectable sarcomas, surgical resection followed by radiotherapy is the principle of local treatment, and perioperative chemotherapy is considered for chemotherapy-sensitive sarcomas. They often originate in anatomical border areas such as the skull base and mediastinum, and they require a multidisciplinary treatment approach considering functional and cosmetic impairment. Moreover, head and neck sarcomas may exhibit different behaviour and characteristics than sarcomas of other areas. In recent years, the molecular biological features of sarcomas have been used for the pathological diagnosis and development of novel agents. This review describes the historical background and recent topics that head and neck oncologists should know about this rare tumour from the following five perspectives: (i) epidemiology and general characteristics of head and neck sarcomas; (ii) changes in histopathological diagnosis in the genomic era; (iii) current standard treatment by histological type and clinical questions specific to head and neck; (iv) new drugs for advanced and metastatic soft tissue sarcomas; and (v) proton and carbon ion radiotherapy for head and neck sarcomas.